ArticleIntensive care medicine2003
Endothelin receptor blockade in canine oleic acid-induced lung injury.
Article in Intensive care medicine, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 15 citations in OpenAlex.
- Current Pharmacological Approach to ARDS: The Place of Bosentan.The Eurasian journal of medicine · 2020Review
- Pathophysiology of pulmonary hypertension in acute lung injury.American journal of physiology. Lung cellular and molecular physiology · 2012Review
- Effect of the endothelin receptor antagonist tezosentan on alpha-naphthylthiourea-induced lung injury in rats.The Kaohsiung journal of medical sciences · 2012Article
- Endothelin-1 impairs alveolar epithelial function via endothelial ETB receptor.American journal of respiratory and critical care medicine · 2009Article
- Preparation and anesthetic properties of propofol microemulsions in rats.Anesthesiology · 2006Article
- Endothelin antagonists: new bullets against lung injury?Critical care (London, England) · 2005Article
- In vitro identification and in silico utilization of interspecies sequence similarities using GeneChip technology.BMC genomics · 2005Article
- Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.Intensive care medicine · 2004Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of endogenous endothelins on pulmonary haemodynamics and gas exchange in oleic acid lung injury.
designProspective experimental study in dogs.
settingAnimal research laboratory in a university teaching hospital. SUBJECTS. Seventeen anaesthetised and ventilated mongrel dogs.
interventionsNine pretreated dogs received an infusion of the endothelin A and B receptor antagonist bosentan (10 mg/kg) started before oleic acid. Eight treated dogs received bosentan started 90 min after oleic acid. Cardiac index (CI) was manipulated by inflating an inferior vena caval balloon or by opening a femoral arterio-venous bypass. MEASUREMENTS AND
resultsPulmonary vascular resistance was defined by measuring the gradient between mean pulmonary artery pressure (MPAP) and occluded PAP (PAOP) at five levels of CI. Intrapulmonary shunt was measured using the inert gas SF(6). Pretreatment with bosentan prevented the oleic acid-induced shift of (MPAP-PAOP)/CI plots to higher pressures, but did not affect the increase in intrapulmonary shunt. Treatment of established oleic acid lung injury with bosentan had no effect.
conclusionsPretreatment, but not treatment, with bosentan, in the dose used, blunted the oleic acid-induced increase in pulmonary vascular resistance, suggesting that endothelins contribute to the increase in pulmonary vascular tone in the early stages of oleic acid lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.